• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Dec. 17 Lupin Ltd has settled patent litigations on allergy drug Desloratadine tablets, the generic version of Schering-Plough’s Clarinex tablets.

Lupin will be licensed under the relevant Desloratadine patents and free to commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances, a note from the company said.

The Mumbai-based drug maker had earlier filed Paragraph IV certification (involving patent litigations) regarding US Patents 6,100,274, 7,214,683 and 7,214,684 — contesting that these patents were either invalid or had not been infringed upon — resulting in the subsequent litigation by Schering Corp and Sepracor.

More Stories on : Corporate Disputes | IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line